AR069272A1 - Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b-)-piridazina su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b-)-piridazina su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR069272A1 AR069272A1 ARP080103097A ARP080103097A AR069272A1 AR 069272 A1 AR069272 A1 AR 069272A1 AR P080103097 A ARP080103097 A AR P080103097A AR P080103097 A ARP080103097 A AR P080103097A AR 069272 A1 AR069272 A1 AR 069272A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- groups
- optionally substituted
- cycloalkyl
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Compuesto de formula general (1), en la que: R2 representa un grupo arilo opcionalmente sustituido con uno o varios sustituyentes elegidos entre los átomos de halogeno y los grupos alquilo C1-6, alquil C1-6-oxi, alquil C1-6-tio, fluoroalquilo C1-6, fluoroalquil C1-6-oxi y -CN; A representa un grupo alquileno C1-7 opcionalmente sustituido con uno o dos grupos Ra; B representa un grupo alquileno C1-7 opcionalmente sustituido con un grupo Rb; L representa bien un átomo de nitrogeno opcionalmente sustituido con un grupo Rc o Rd, o bien un átomo de carbono sustituido con un grupo Re1 y un grupo Rd o dos grupos Re2; estando los átomos de carbono de A y de B opcionalmente sustituidos con uno o varios grupos Rf idénticos o diferentes el uno del otro; Ra, Rb y Rc se definen de forma que: dos grupos Ra pueden formar juntos un grupo alquileno C1-6; Ra y Rb pueden formar juntos un enlace o un grupo alquileno C1-6; Ra y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rb y Rc pueden formar juntos un enlace o un grupo alquileno C1-6; Rd representa un grupo elegido entre el átomo de hidrogeno y los grupos alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, hidroxi-alquilo C1-6, alquil C1-6-oxi-alquilo C1-6, alquil C1-4-tio-alquilo C-1-6, fluoroalquilo C1-6 y bencilo; Re1 representa un grupo -NR4R5 o una monoamina cíclica que comprende opcionalmente un átomo de oxigeno, estado la monoamina cíclica opcionalmente sustituida con uno o varios sustituyentes elegidos entre el átomo de fluor y los grupos alquilo C1-6, alquil C1-6-oxi o hidroxilo; dos Re2 forman con el átomo de carbono que les soporta una monoamina cíclica que comprende opcionalmente un átomo de oxígeno, estando esta monoamina cíclica opcionalmente sustituida con uno o varios grupos Rf idénticos o diferentes el uno del otro; Rf representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alquil C1-6-oxi-alquilo C1-6, hidroxi-alquilo C1-6, fluoroalquilo C1-6 o bencilo; R4 y R5 representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7o cicloalquil C3-7-alquilo C1-6, R7 y R8 representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-6; en estado de base o de sal de adicion a un ácido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95071107P | 2007-07-19 | 2007-07-19 | |
| FR0705224A FR2918986B1 (fr) | 2007-07-19 | 2007-07-19 | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069272A1 true AR069272A1 (es) | 2010-01-13 |
Family
ID=39183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103097A AR069272A1 (es) | 2007-07-19 | 2008-07-18 | Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b-)-piridazina su preparacion y su aplicacion en terapeutica |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8455491B2 (es) |
| EP (1) | EP2178879B1 (es) |
| JP (1) | JP5431319B2 (es) |
| KR (1) | KR20100041771A (es) |
| CN (1) | CN101784552A (es) |
| AR (1) | AR069272A1 (es) |
| AU (1) | AU2008300449A1 (es) |
| BR (1) | BRPI0814510A2 (es) |
| CA (1) | CA2693116A1 (es) |
| CL (1) | CL2008002138A1 (es) |
| CO (1) | CO6290690A2 (es) |
| EA (1) | EA016376B1 (es) |
| ES (1) | ES2429765T3 (es) |
| FR (1) | FR2918986B1 (es) |
| MA (1) | MA31616B1 (es) |
| NZ (1) | NZ582683A (es) |
| PA (1) | PA8789901A1 (es) |
| PE (1) | PE20090493A1 (es) |
| TW (1) | TW200914456A (es) |
| UY (1) | UY31236A1 (es) |
| WO (1) | WO2009037394A2 (es) |
| ZA (1) | ZA201001214B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) * | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| HUE043962T2 (hu) * | 2009-10-23 | 2019-09-30 | Janssen Pharmaceutica Nv | Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok |
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CN103097380B (zh) * | 2010-08-09 | 2015-06-03 | 株式会社创药分子设计 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| JP6283688B2 (ja) * | 2012-12-21 | 2018-02-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン |
| WO2014100533A1 (en) | 2012-12-21 | 2014-06-26 | Bristol-Myers Squibb Company | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CN106029075A (zh) * | 2014-01-09 | 2016-10-12 | 细胞内治疗公司 | 有机化合物 |
| CN108883110B (zh) | 2016-03-10 | 2022-05-27 | 詹森药业有限公司 | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 |
| CA3032432A1 (en) | 2016-08-03 | 2018-02-08 | Charles A. Mcwherter | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| SG11202007422QA (en) | 2018-02-05 | 2020-09-29 | Alkermes Inc | Compounds for the treatment of pain |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| EP4031132A4 (en) | 2019-09-19 | 2023-09-13 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2021190615A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
| US6555328B1 (en) | 1999-06-08 | 2003-04-29 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3 |
| RS50823B (sr) * | 2003-12-11 | 2010-08-31 | Aventis Pharmaceuticals Inc. | Supstituisani 1h-pirolo[3,2-b, 3,2-c, i 2,3-c]piridin-2-karboksamidi i srodni analozi kao inhibitori kazein kinaze i epsilon |
| CA2555263A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| US20100216798A1 (en) * | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2007
- 2007-07-19 FR FR0705224A patent/FR2918986B1/fr active Active
-
2008
- 2008-07-15 PA PA20088789901A patent/PA8789901A1/es unknown
- 2008-07-17 TW TW097127189A patent/TW200914456A/zh unknown
- 2008-07-17 PE PE2008001220A patent/PE20090493A1/es not_active Application Discontinuation
- 2008-07-17 UY UY31236A patent/UY31236A1/es not_active Application Discontinuation
- 2008-07-18 NZ NZ582683A patent/NZ582683A/en not_active IP Right Cessation
- 2008-07-18 WO PCT/FR2008/001057 patent/WO2009037394A2/fr not_active Ceased
- 2008-07-18 EA EA201070161A patent/EA016376B1/ru not_active IP Right Cessation
- 2008-07-18 CL CL2008002138A patent/CL2008002138A1/es unknown
- 2008-07-18 KR KR1020107001087A patent/KR20100041771A/ko not_active Withdrawn
- 2008-07-18 BR BRPI0814510-5A2A patent/BRPI0814510A2/pt not_active IP Right Cessation
- 2008-07-18 CA CA2693116A patent/CA2693116A1/fr not_active Abandoned
- 2008-07-18 EP EP08831515.5A patent/EP2178879B1/fr active Active
- 2008-07-18 ES ES08831515T patent/ES2429765T3/es active Active
- 2008-07-18 AU AU2008300449A patent/AU2008300449A1/en not_active Abandoned
- 2008-07-18 JP JP2010516539A patent/JP5431319B2/ja not_active Expired - Fee Related
- 2008-07-18 CN CN200880103986A patent/CN101784552A/zh active Pending
- 2008-07-18 AR ARP080103097A patent/AR069272A1/es unknown
-
2010
- 2010-01-11 US US12/685,030 patent/US8455491B2/en not_active Expired - Fee Related
- 2010-01-19 CO CO10004823A patent/CO6290690A2/es not_active Application Discontinuation
- 2010-02-17 MA MA32629A patent/MA31616B1/fr unknown
- 2010-02-19 ZA ZA2010/01214A patent/ZA201001214B/en unknown
-
2013
- 2013-05-06 US US13/887,845 patent/US9108971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010533686A (ja) | 2010-10-28 |
| FR2918986B1 (fr) | 2009-09-04 |
| CL2008002138A1 (es) | 2009-10-23 |
| ES2429765T3 (es) | 2013-11-15 |
| CO6290690A2 (es) | 2011-06-20 |
| MA31616B1 (fr) | 2010-08-02 |
| PA8789901A1 (es) | 2009-02-09 |
| NZ582683A (en) | 2011-07-29 |
| JP5431319B2 (ja) | 2014-03-05 |
| BRPI0814510A2 (pt) | 2015-02-03 |
| US20100152157A1 (en) | 2010-06-17 |
| EA016376B1 (ru) | 2012-04-30 |
| KR20100041771A (ko) | 2010-04-22 |
| US9108971B2 (en) | 2015-08-18 |
| EP2178879B1 (fr) | 2013-07-03 |
| PE20090493A1 (es) | 2009-05-27 |
| US8455491B2 (en) | 2013-06-04 |
| EP2178879A2 (fr) | 2010-04-28 |
| TW200914456A (en) | 2009-04-01 |
| US20130245023A1 (en) | 2013-09-19 |
| AU2008300449A1 (en) | 2009-03-26 |
| EA201070161A1 (ru) | 2010-08-30 |
| CA2693116A1 (fr) | 2009-03-26 |
| WO2009037394A2 (fr) | 2009-03-26 |
| ZA201001214B (en) | 2011-05-25 |
| UY31236A1 (es) | 2009-03-02 |
| FR2918986A1 (fr) | 2009-01-23 |
| CN101784552A (zh) | 2010-07-21 |
| WO2009037394A3 (fr) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069272A1 (es) | Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b-)-piridazina su preparacion y su aplicacion en terapeutica | |
| AR069269A1 (es) | Derivados de 6- cicloamino -3- (piridin-il) imidazo (1,2-beta)- piridazina, su preparacion y su aplicacion en terapeutica | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| PE20110368A1 (es) | Moduladores de mif | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| CO6640226A2 (es) | 5-fluoro-1h-pirazolipiridinas sustituidas y su uso | |
| NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
| CO6150146A2 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
| EP3956210A4 (en) | Davit arm base | |
| PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR074795A1 (es) | Derivados de 6-cicloamino-2-tienil-3-(piridin-4-il)imidazo[1,2-b]-piridazina y 6-cicloamino-2-furanil-3-(piridin-4-il)imidazo[1,2-b]-piridazina, su preparacion y su aplicacion en enfermedades que implican la caseina quinasa 1 y/o caseina quinasa 1 delta | |
| AR061377A1 (es) | Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares. | |
| AR066603A1 (es) | Derivados de arilamida pirimidona | |
| IL312125A (en) | Rxfp1 agonists | |
| EP4353794A4 (en) | Pressure-sensitive adhesive tape | |
| DE112020002376A5 (de) | Multi-chip trägerstruktur | |
| AR074237A1 (es) | Derivados de 6- cicloamino -3-(1h- pirrolo (2,3-beta ) piridin -4-il) imidazo (1,2-beta )piridazina, su preparacion y su aplicacion en terapeutica | |
| CO6602113A2 (es) | Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéutico | |
| AR075838A1 (es) | Derivados de n-((6-aza-biciclo(3.2.1)oct-5-il)-aril-metil)-heterobenzamida, su preparacion y su aplicacion en terapeutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |